Reach Us +44-1647-403003
MicroRNA Expression In Advanced Breast Cancer | 65562
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

MicroRNA expression in advanced breast cancer

Global Summit on Oncology & Cancer

Lei Huo

University of Texas, USA

Keynote: J Cancer Sci Ther

DOI: 10.4172/1948-5956-C1-098

Statement of the Problem: Although early stage breast cancer has a high cure rate with current treatment modalities, advanced breast cancer remains a life threatening disease. There is an urgent need for new therapeutic targets. Inflammatory breast cancer, comprising 1-5% of newly diagnosed breast cancer in the United States, is the most aggressive form of breast cancer, characterized by clinical hallmarks of diffuse erythema and edema and rapid progression from the onset. Recent advances have implicated the role of microRNAs as oncogenes or tumor suppressor genes in tumorigenesis, metastasis and response to treatment in various cancer types including breast cancer. The aim of our ongoing study is to identify microRNA molecules that are regulated in advanced breast cancer, including inflammatory breast cancer. Methodology & Theoretical Orientation: MicroRNA expression profiles of human advanced breast cancer including inflammatory breast cancer were compared to normal breast tissue using a previously validated microRNA microarray assay. The results were subsequently validated by quantitative reverse transcription PCR and in situ hybridization. Findings: There was distinct segregation between tumor and normal breast tissue in microRNA expression profiles. In contrast, between inflammatory breast cancer and non-inflammatory breast cancer, distinct clustering was not readily identified in the microarray analysis. However, several microRNAs were differentially expressed in inflammatory breast cancer. We have validated some molecules by quantitative PCR and in situ hybridization. For example, miR-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with non-inflammatory breast cancer. Lower expression of miR-205 was associated with worse distant metastasis-free survival and overall survival in our cohort. Conclusion & Significance: MicroRNAs may serve as therapeutic targets in advanced breast cancer.

Lei Huo is a practicing Breast Pathologist in The University of Texas MD Anderson Cancer Center. She is actively involved in clinical and translational research in the field of Breast Cancer. Her research interests include molecular and immunohistochemical markers in tumorigenesis, diagnosis and treatment of breast cancer, among others.

Email: [email protected]

Relevant Topics